| 9.9999997E-5 -0 (-0%) | 08-13 09:30 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Molecular Templates, Inc. (MTEM) is a clinical-stage biopharmaceutical firm dedicated to the identification and progression of biological therapies for oncology and other significant health conditions. The company's core development strategy relies on its unique engineered toxin body (ETB) drug platform to construct a robust pipeline of treatments. Currently, several of its ETB candidates are undergoing Phase I clinical evaluation: MT-5111 is being assessed for HER2-positive cancers; MT-0169 is in trials for individuals with relapsed or refractory myeloma; and MT-6402 targets patients who have not responded to prior PD-1/PD-L1 antibody treatments. Beyond these, Molecular Templates is also developing ETBs to engage other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. Furthermore, the company has forged a collaborative partnership with Bristol Myers Squibb to jointly discover and advance innovative ETB-based products designed for a diverse array of biological targets. Established in 2001, Molecular Templates, Inc. is headquartered in Austin, Texas.
Tue, 07 Jul 2026
Molecular Templates outlines its ADC platform strategy as a clinical-stage biotech - Ad-hoc-news.de
Fri, 23 May 2025
Austin cancer drug company Molecular Templates shuts down - The Business Journals
Thu, 24 Apr 2025
Molecular Templates (MTEM) Stock Price, News & Analysis - Stock Titan
Thu, 24 Apr 2025
Molecular Templates enters bankruptcy, secures DIP financing - Investing.com
Fri, 20 Dec 2024
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18% - Investing.com
Wed, 12 Apr 2023
FDA Halts Phase 1 Study MT-0169 Due to Unacceptable Toxicity - Targeted Oncology
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|